Edgewise Therapeutics, Inc. (EWTX)
2025-06-30 | ||||
|---|---|---|---|---|
| Unrealized loss on available-for-sale securities | -197 | |||
| Interest income | 6,495 | |||
| Total other income | 6,495 | |||
| Research and development | 33,558 | |||
| General and administrative | 9,052 | |||
| Total operating expenses | 42,610 | |||
| Loss from operations | -42,610 | |||
| Net loss | -36,115 | |||
| Total comprehensive loss | -36,312 | |||
| Earnings per share, basic | -0.34 | |||
| Earnings per share, diluted | -0.34 | |||
| Weighted average number of shares outstanding, basic | 104,940,493 | |||
| Weighted average number of shares outstanding, diluted | 104,940,493 | |||